Use of an anti-Tau pS422 antibody for the treatment of brain diseases

US9290567B2 · kind B2 · utility

Assignee

• Hoffmann-La Roche Inc. · US

Inventors

• Bernd Bohrmann · Glückstadt, DE
• Ulrich Goepfert · Penzberg, DE
• Fiona Grueninger · Arlesheim, CH
• Walter Huber · Kaiseraugst, CH
• Hans-Willi Krell · Penzberg, DE
• Valeria Lifke · Penzberg, DE
• Olaf Mundigl · Weilheim, DE
• Sonja Offner · Penzberg, DE
• Laurence Ozmen · Rixheim, FR
• Michael Schraemi · Penzberg, DE

Key dates

• Filing date: Jun 6, 2013
• Grant date: Mar 22, 2016
• Expiry date: Sep 8, 2033

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/55
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

An antibody binding to Tau that is phosphorylated at serine 422 (pS422), which specifically binds to phosphorylated Tau fragment of SEQ ID NO:9 and to Tau pS422, but does not bind to Tau and to phosphorylated MCAK fragment of SEQ ID NO:17. The antibody is useful in the treatment of a Tauopathy.